Expression, purification and characterization of three overlapping immunodominant recombinant fragments from Bordetella pertussis filamentous hemagglutinin

Avicenna Journal of Medical Biotechnology

Volumn 5, Issue 1, 2013, Pages 20-28

  Asgarian Omran, Hossein ^a,b   Amirzargar, Ali Akbar ^a   Arjmand, Hossein ^c   Eshraghian, Mohammadreza ^b   Nikbin, Behrooz ^a   Eshraghi, Saeid ^b   Mahdavi, Marzieh ^d   Khoshnoodi, Jalal ^b   Jeddi Tehrani, Mahmood ^d   Rabbani, Hodjatallah ^d   Shokri, Fazel ^b,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Bordetella pertussis; Filamentous hemagglutinin; Immunodominant; Probaryotic expression; Recombinant antigen

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL DNA; BACTERIAL PROTEIN; EPITOPE; FILAMENTOUS HEMAGGLUTININ; GAMMA INTERFERON; GENOMIC DNA; HEMAGGLUTININ; PERTUSSIS VACCINE; POLYHISTIDINE TAG; RECOMBINANT PROTEIN; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; WESTERN BLOTTING;

EID: 84873203330     PISSN: 20082835     EISSN: 20084625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 2006;367(9526):1926-1936. (Pubitemid 43831996)
2. Marzouqi I, Richmond P, Fry S, Wetherall J, Mukkur T. Development of improved vaccines against whooping cough: current status. Hum Vaccin 2010;6(7):543-553.
3. Berbers GA, De Greeff SC, Mooi FR. Improving pertussis vaccination. Hum Vaccin 2009;5(7):497-503.
4. Xu Y, Zhang S, Bolgiano B, Tan Y, Asokanathan C, Zhang H, et al. Comparison of recombinant and native pertactin of Bordetella pertussis. Vaccine 2011;29(10):1974-1980.
5. Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012;5(5):485-500.
6. Mazar J, Cotter PA. Topology and maturation of filamentous haemagglutinin suggest a new model for two-partner secretion. Mol Microbiol 2006;62(3):641-654. (Pubitemid 44571591)
7. Colombi D, Horton DS, Oliveira ML, Sakauchi M A, Ho PL. Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of Bordetella pertussis are able to inhibit hemagglutination induced by the whole adhesin. FEMS Microbiol Lett 2004;240(1):41-47. (Pubitemid 39421788)
8. Knight JB, Huang YY, Halperin SA, Anderson R, Morris A, Macmillan A, et al. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Clin Exp Immunol 2006;144(3):543-551. (Pubitemid 43799939)
9. Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD. Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD lib/CD 18) binds filamentous hemagglutinin of Bordetella pertussis. Cell 1990;61(7):1375-1382.
10. Prasad SM, Yin Y, Rodzinski E, Tuomanen EI, Masure HR. Identification of a carbohydrate recognition domain in filamentous hemagglutinin from Bordetella pertussis. Infect Immun 1993;61(7):2780-2785. (Pubitemid 23182269)
11. Hannah JH, Menozzi FD, Renauld G, Locht C, Brennan MJ. Sulfated glycoconjugate receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the heparin binding domain on FHA. Infect Immun 1994;62(11):5010-5019. (Pubitemid 24332809)
12. Di Tommaso A, Domenighini M, Bugnoli M, Tagliabue A, Rappuoli R, De Magistris MT. Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses. Infect Immun 1991;59(9):3313-3315.
13. Leininger E, Bowen S, Renauld-Mongenie G, Rouse JH, Menozzi FD, Locht C, et al. Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin. J Infect Dis 1997;175(6):1423-1431. (Pubitemid 27225046)
14. Del Giudice G, Rappuoli R. Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 1999;17(Suppl2):S44-52. (Pubitemid 29457535)
15. Shabani M, Asgarian-Omran H, Hojjat-Farsangi M, Vossough P, Sharifian RA, Toughe GR, et al. Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. Avicenna J Med Biotech 2011;3(3):119-25.
16. Cherry JD. The present and future control of pertussis. Clin Infect Dis 2010;51(6):663-667.
17. Nascimento IP, Dias WO, Mazzantini RP, Miyaji EN, Gamberini M, Quintilio W, et al. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit SI induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun 2000;68(9):4877-4883.
18. Lee SF, Halperin SA, Knight JB, Tait A. Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii. Appl Environ Microbiol 2002;68(9):4253-4258. (Pubitemid 34988103)
19. Jinyong Z, Xiaoli Z, Weijun Z, Ying G, Gang G, Xuhu M, et al. Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development. Mol Biol Rep 2011;38(3):1957-1963.
20. Khafri A, Aghaiypour K, Najar Peerayeh S, Ghorbani R. Cloning and expression of SI subunit of pertussis toxin in Escherichia coli. Avicenna J Med Biotech 2011;3(1):19-24.
21. Relman DA, Domenighini M, Tuomanen E, Rappuoli R, Falkow S. Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc Natl Acad Sci USA 1989;86(8):2637-2641. (Pubitemid 19112602)
22. Delisse-Gathoye AM, Locht C, Jacob F, Raaschou-Nielsen M, Heron I, Ruelle JL, et al. Cloning, partial sequence, expression, and antigenic analysis of the filamentous hemagglutinin gene of Bordetella pertussis. Infect Immun 1990;58(9):2895-2905. (Pubitemid 20267677)
23. Renauld-Mongenie G, Cornette J, Mielcarek N, Menozzi FD, Locht C. Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. J Bacteriol 1996;178(4):1053-1060. (Pubitemid 26048021)
24. Wilson DR, Siebers A, Finlay BB. Antigenic analysis of Bordetella pertussis filamentous hemagglutinin with phage display libraries and rabbit antifilamentous hemagglutinin polyclonal antibodies. Infect Immun 1998;66(10):4884-4894. (Pubitemid 28453096)
25. Piatti G. Identification of immunodominant epitopes in the filamentous hemagglutinin of Bordetella pertussis. FEMS Immunol Med Microbiol 1999;23(3):235-241. (Pubitemid 29132810)
26. Alonso S, Reveneau N, Pethe K, Locht C. Eightykilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role. Infect Immun 2002;70(8):4142-4147. (Pubitemid 34790922)